Objective: The hypothalamic control of energy balance is regulated by a complex network of neuropeptide-releasing neurons. Although the effect of these neuropeptides on individual aspects of energy homoeostasis has been studied, the coordinated response of these effects has not been comprehensively investigated. We have simultaneously monitored a number of metabolic parameters following intracerebroventricular (ICV) administration of 1 and 3 nmol of neuropeptides with established roles in the regulation of feeding, activity and metabolism. Ad libitum-fed rats received the orexigenic neuropeptides neuropeptide Y (NPY), agouti-related protein (AgRP), melanin-concentrating hormone (MCH) or orexin-A. Overnight-food-deprived rats received an ICV injection of the anorectic peptides a-melanocyte-stimulating hormone (MSH), corticotrophin-releasing factor (CRF) or neuromedin U (NMU). Results: Our results reveal the temporal sequence of the effects of these neuropeptides on both energy intake and expenditure, highlighting key differences in their function as mediators of energy balance. NPY and AgRP increased feeding and decreased oxygen consumption, with the effects of AgRP being more prolonged. In contrast, orexin-A increased both feeding and oxygen consumption, consistent with an observed increase in activity. The potent anorexigenic effects of CRF were accompanied by a prolonged increase in activity, whereas NMU injection resulted in significant but short-lasting inhibition of food intake, ambulatory activity and oxygen consumption. a-MSH injection resulted in significant increases in both ambulatory activity and oxygen consumption, and reduced food intake following administration of 3 nmol of the peptide. Conclusion: We have for the first time, simultaneously measured several metabolic parameters following hypothalamic administration of a number of neuropeptides within the same experimental system. This work has shown the interrelated effects of these neuropeotides on activity, energy expenditure and food intake, thus facilitating comparison between the different hypothalamic systems.
Introduction
Energy balance in mammals is a highly regulated physiological process and is maintained by a homoeostatic system involving both the central nervous system and the periphery. The hypothalamus and the brainstem are central nervous system sites critical in the regulation of energy homoeostasis. Reciprocal neuronal connections exist between these two regions, which, in response to peripheral signals of nutritional status, regulate both short-and longterm energy homoeostasis.
The hypothalamus contains an extensive neuronal network, which releases neuropeptides in a coordinated manner and contributes to the physiological responses to changes in nutritional status. The regulation of energy homoeostasis integrates energy intake (i.e. food intake) with energy outputs, such as resting metabolic rate, activity and thermogenesis. The neuropeptides within the hypothalamus that regulate energy homoeostasis specifically influence energy intake and energy output to exert their overall effect on energy balance. Thus, determining the coordinated effects of specific neuropeptides on energy intake, behaviour and energy expenditure is essential to understanding their physiological role.
The hypothalamic circuits controlling energy homoeostasis are still to be precisely determined. The best characterized neuronal populations involved in the regulation of appetite and energy expenditure are the orexigenic neuropeptide Y (NPY)/agouti-related protein (AgRP) neuron and the anorexigenic pro-opiomelanocortin neuron located in the arcuate nucleus (Arc). The Arc is located at the base of the hypothalamus and is incompletely isolated by the blood-brain barrier. Thus, it is able to be directly influenced by peripherally circulating signals of acute food intake and nutritional status. Neuronal populations in the Arc respond to these circulating factors and signal to extrahypothalamic regions such as the brainstem, as well as other hypothalamic nuclei, including the paraventricular nucleus (PVH) and lateral hypothalamic area, where they influence second-order neurons. 1 These include melaninconcentrating hormone (MCH) and orexin-A neurons, located primarily in the lateral hypothalamic area, 2, 3 corticotrophin-releasing factor (CRF) neurons, found predominantly in the PVH, 4 and neurons-releasing neuromedin U (NMU), which in turn interact with the NMU2R located in the PVH. 5 Although the effects of these neuropeptides on food intake and energy expenditure have been studied, they have not been comprehensively and simultaneously measured in the same experimental system. The Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments, Columbus, OH, USA) enables 24 h profiles of food intake, activity and energy expenditure to be determined. Simultaneous measurements of food intake, activity and energy expenditure allow the comprehensive metabolic effects of specific neuropeptides to be determined.
To further understand the complex responses involved in appetite regulation, we studied the role of the Arc neuropeptides NPY, AgRP and a-MSH (a product of the pro-opiomelanocortin gene), the predominantly PVH neuropeptides CRF and NMU, and the lateral hypothalamic area neuropeptides MCH and orexin-A in the regulation of energy balance. The coordinated effects of intracerebroventricular (ICV) administration of these neuropeptides on food intake, oxygen consumption, respiratory exchange ratio (RER) and activity were determined using the CLAMS. These comprehensive measurements provide further insight into the roles of these peptides in the regulation of the specific components of energy balance.
Materials and methods

Animals
Male Wistar rats (specific pathogen free; Charles River, Margate, UK), weighing 300-350 g, were maintained in individual cages under controlled temperature (21-23 1C) and light (12:12 light-dark cycle, lights on at 0700 h) with ad libitum access to food (RM1 diet, SDS Ltd, Witham, UK) and water. Animal procedures were approved under the British Home Office Animals (Scientific Procedures) Act 1986 (Project Licence 70/6402).
Materials
Cannulation materials were purchased from Plastics One, Inc. (Roanoke, VA, USA). Rat CRF, orexin-A and a-MSH were synthesized by Bachem (St Helen's, UK). NMU-23 was synthesized by IAF Biochem International (Quebec, ON, Canada). MCH and AgRP (83-132) were synthesized by the Peptide Institute (Osaka, Japan). NPY was synthesized as described previously. 6 
ICV cannulation and injection
Animals were implanted with a permanent 22-gauge stainless steel cannula projecting to the third ventricle as described earlier. 7 Animals were allowed for 7 days recovery after surgery and were then accustomed to handling and being weighed on a daily basis. All compounds were injected using a 28-gauge stainless steel injector placed in and projecting 1 mm below the tip of the cannula. Cannula placement was confirmed by a positive dipsogenic response to angiotensin II (50 ng/rat). Only those animals with a positive dipsogenic response were included in the data analysis. Three days after the angiotensin II injection, all animals were habituated to the injection process by receiving a single injection of 5 ml saline injected over 1 min as described previously. 7 Study design ICV cannulated animals were monitored using a 24-chamber open-circuit Oxymax CLAMS (Columbus instruments). Individually housed rats were maintained at 21-23 1C under a 12:12 h light-dark cycle (light period: 0700-1900 h). Powdered RM1 diet (SDS Ltd) and water were available ad libitum unless otherwise stated. Animals were individually housed in plexiglass cages, through which air was passed at a flow rate of 2.5 l/min. Before all metabolic cage studies, rats were acclimatized to their cages for 48 h to generate a stable metabolic background against which to test the effects of the neuropeptides.
Baseline studies
To generate reference data for subsequent neuropeptide studies, baseline data were recorded in ad libitum-fed and food-deprived animals. Ad libitum-fed rats (n ¼ 24) were placed in the CLAMS metabolic cages for 48 h and then food deprived for an additional 24 h. Metabolic parameters (VO 2 and VCO 2 ) were measured by indirect calorimetry. Exhaust air from each chamber was sampled at 30 min Activity counts in x and z axes were recorded every minute for 24 h and were used to determine ambulatory movement on the X axis (XAMB) and total beam breaks on the Z axis (ZTOT), respectively. Food intake was measured every minute.
ICV injection studies
A dose of 3 nmol has been shown earlier to cause a robust effect on food intake for all neuropeptides examined in this study. 5, 6, [9] [10] [11] [12] On the basis of this data, we have administered 1 and 3 nmol of each peptide studied to facilitate the direct comparison of their effects. VCO 2 , VO 2 , activity (horizontal and vertical) and cumulative food intake were monitored as described above.
Satiated studies
Ad libitum-fed rats received a single ICV injection of either saline or peptide (NPY, AgRP, MCH or orexin-A) (n ¼ 8 per group) at doses of either 1 or 3 nmol in the early light phase (0900-1000 h).
Food-deprived studies
Rats were food deprived for 20 h before injection. All rats received a single injection of either saline or peptide (a-MSH, CRF or NMU) (n ¼ 8 per group) at doses of 1 or 3 nmol in the early light phase (0900-1000 h). Animals were returned to their home cage with ad libitum access to food.
Statistics
Statistical advice was provided by J Eliahoo at the Statistical Advisory Service, Imperial College London. For all parameters, differences between the treatment groups were determined using the Mann-Whitney U-test (Stata 9, Statacorp, College Station, TX, USA). All significant effects of neuropeptides were recorded in the initial 12 h post injection and are presented as such, with the exception of AgRP, which is shown as a 24-h profile. In all cases, Po0.05 was considered to be statistically significant. All feeding data are presented as percentage of saline to facilitate comparison between different neuropeptide treatments.
Results
Twenty-four hour baseline readings of food intake, activity and energy expenditure in ad libitum-fed and food-deprived rats Increased levels of feeding and locomotor activity occurred during the dark phase compared with the light phase. These activities exhibited a bimodal pattern, with levels peaking at the beginning and end of the dark phase ( Figure 1 ). Corresponding with these diurnal variations, VO 2 and RER were also elevated during the dark phase, whereas fasting resulted in a reduction in VO 2 and VCO 2 during the dark phase ( Figure 1 ).
Neuropeptide Y ICV injection of either 1 or 3 nmol NPY resulted in an immediate increase in food intake, 5 min (3 nmol) and 10 min (1 nmol) post injection (Table 1; Figure 2 ). A significant increase in XAMB was also observed by 1 h post injection, with the 3-nmol dose of NPY causing a more sustained effect (Table 1 ; Figure 3 ). A similar pattern was also seen for ZTOT (data not shown). Despite the increase in activity, ICV administration of either dose of NPY caused a significant decrease in VO 2 (Table 1; Figure 4 ) and a significant increase in RER ( Figure 5 ).
Agouti-related protein
A single ICV injection of either 1 or 3 nmol AgRP produced a significant increase in food intake with the effect lasting throughout the remaining 24 h measurement period (Table 1 ; Figure 2 ). During the dark phase, significant reductions in XAMB were observed in AgRP-injected animals ( Table 1 ; Figure 3 ). These reductions in XAMB coincided with the peaks in activity at the beginning and the end of the dark phase observed in saline-injected controls ( Figure 3 ). A similar pattern was also seen in ZTOT (data not shown).
There was a trend towards a decrease in VO 2 in AgRP-treated animals compared with saline controls; however, this did not achieve statistical significance ( Figure 4 ). A significant increase in RER was observed following administration of 1 or 3 nmol AgRP ( Figure 5 ).
Orexin-A
A trend towards an increase in food intake was observed for 3 h following a single injection of either 1 or 3 nmol orexin-A. This effect, however, did not reach statistical significance ( Figure 2) . In contrast to the non-significant effects on feeding, a rapid and potent increase in locomotion was observed at both doses (Table 1; Figure 3 ). A similar pattern was observed with ZTOT (data not shown). Consistent with the effects on activity, an increase in VO 2 was also observed at 1 and 3 nmol doses (Table 1; Figure 4 ). No effect was seen on RER ( Figure 5 ).
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Melanin-concentrating hormone
A trend towards a stimulation in feeding was observed at 30 min following a single ICV injection of either dose of MCH; however, this effect did not reach statistical significance ( Supplementary Figure 1) . A small decrease in VO 2 at 30 min post injection and a small rise in RER lasting up to 4 h post injection, neither of which reached statistical significance, were also recorded ( Supplementary Figure 1) .
a-Melanocyte-stimulating hormone
A single ICV injection of 3 nmol a-MSH rapidly decreased food intake in food-deprived rats (Table 1; Figure 2 ). No statistically significant effects on food intake were observed with 1 nmol a-MSH. There was a small but significant increase in XAMB at both 1 and 3 nmol doses (Table 1 ; Figure 3 ). A similar pattern was observed for ZTOT (data not shown). A rapid and dramatic increase in VO 2 was observed by 30 min post injection in animals receiving either 1 or 3 nmol a-MSH (Table 1 ; Figure 4 ). Injection of both 1 and 3 nmol of a-MSH also resulted in a significantly reduced RER ( Figure 5 ).
Corticotrophin-releasing factor
A rapid and potent reduction in food intake was seen following a single ICV injection of either 1 or 3 nmol CRF. Food intake was significantly lower than saline controls by 10 and 15 min post injection for 1 and 3 nmol, respectively, and remained significantly lower for the duration of the 24-h measurement period (Table 1 ; Figure 2 ). The decrease in food intake was accompanied by a prolonged stimulation of XAMB (Table 1 ; Figure 3 ). A similar pattern was also observed for ZTOT (data not shown). In addition, an increase in VO 2 was also observed. This, however, was not as prolonged as the effect seen on food intake and activity, and was only significant from 30 min to 1 h post injection for both doses (Table 1; Figure 4 ). RER was significantly reduced following administration of both doses of CRF ( Figure 5 ).
Neuromedin U
A single ICV injection of either 1 or 3 nmol NMU significantly reduced food intake (Table 1; Figure 2) . A rapid and significant increase in XAMB was also observed (Table 1; Figure 3 ). A similar pattern was also observed for ZTOT (data not shown). In addition, 1 and 3 nmol NMU significantly increased VO 2 by 30 min post injection (Table 1; Figure 4 ). A small decrease in RER was also seen at 1 h post injection, in accordance with the reduction in food intake ( Figure 5 ).
Discussion
Understanding the coordinated effects of neuropeptides involved in energy intake, behaviour and energy expenditure is necessary to determine their physiological role in the regulation of energy homoeostasis. The changes observed in energy expenditure in our studies are influenced by alterations in physical activity, thermogenesis and food intake in rats. In a food-deprived state, energy expenditure and activity are reduced as a means of conserving energy, Under ad libitum-fed conditions, rats on a 12-h light:dark cycle consume most of their daily food intake during the dark phase with peaks at the beginning and end of this period. 13, 14 The increase in food intake at the beginning of the dark phase is thought to be due to an energy deficiency from the preceding light phase, during which food intake is relatively low. 15 The increase in food intake at the end of the dark phase may exist to ensure sufficient energy availability throughout the light phase. 16 In this study, all the animals were injected in the early light phase. Orexigenic neuropeptides were administered to ad libitum fed rats, whereas anorectic neuropeptides were injected in food-deprived rats. These models were used in accordance with work published earlier by ourselves and others. [17] [18] [19] It has been shown, however, that the time of day that a peptide is administered can have an effect on its potency and duration of action. 20 Had the rats been injected at different times during the light/dark cycle, for example, at the beginning of the dark phase, different food intake, activity and energy expenditure profiles may have been observed. Similarly, administering the orexigenic neuropeptides to food-deprived rats and the anorectic neuropep-tides to ad libitum-fed rats would also likely have resulted in different profiles. Thus, although our experiments demonstrate the effects of the neuropeptides in the same experimental system, their results cannot be assumed to be applicable to rats injected under different experimental conditions.
Physiologically, neuropeptides are released in coordinated fashion in response to changes in energy balance. It is possible to study the effects of administering more than one neuropeptide on energy balance. For example, co-administration of NPY and AgRP has been shown to additively increase food intake compared with each peptide alone. 20 Unfortunately, little is known regarding the concentrations of neuropeptides released or their specific sites of action within the hypothalamus under different physiological conditions. It is, therefore, currently impossible to accurately mimic physiology by administering combinations of neuropeptides. We administered neuropeptides individually, which can provide useful data regarding the role of these signals, but does not mimic physiological conditions. Continuous measurements revealed the unique food intake profiles of each neuropeptide. A marked stimulation of food intake was seen following ICV administration of NPY and AgRP in line with earlier published data, 21, 22 whereas MCH and orexin-A were less potent, resulting in a nonsignificant (P ¼ 0.09) increase in food intake. Earlier studies have shown a significant increase in food intake following Neuropeptides and energy balance NM Semjonous et al ICV injection of MCH and orexin at equivalent doses. 2, 12, 23 The differing food intake profiles from our studies highlight the characteristics of specific neuropeptide signalling pathways. For example, ICV administration of NPY caused an immediate and potent increase in food intake, which was relatively short-lived compared with the orexigenic effects of AgRP, which only became statistically significant 3 h after injection and lasted for the duration of the study. Interestingly, AgRP caused a significant reduction in XAMB during the dark phase, 12 h post injection. It is possible that AgRP has similar suppressive effects on activity, as measured using XAMB, in the light phase, but that these effects are difficult to discern against the low activity of the control animals during this period. The mechanism by which AgRP reduces activity is unclear and requires further investigation. The increased RER values of AgRP-injected animals likely reflect their increased food intake leading to increased use of carbohydrate as fuel source. Aside from a slight decrease in dark phase ambulatory activity, no discernible differences between the 1-and 3-nmol doses of AgRP were detected. If the experiment had continued beyond 24 h, it is possible that a distinction between high and low doses may have been observed. Despite NPY and AgRP largely being secreted from the same neurons in the Arc, 24 the different food intake, activity and energy expenditure profiles exhibited following ICV administration into rats in the present studies highlight their distinct effects. In rats, fasting or a reduction in food intake will usually result in a reduction in energy expenditure as the body acts to conserve energy stores. Interestingly, following the administration of specific neuropeptides, changes in energy expenditure were contrary to those predicted from the 
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NM Semjonous et al observed changes in food intake alone. For example, NPY and orexin-A both stimulated food intake, but orexin-A increased energy expenditure, whereas NPY reduced it. This coordinated metabolic response to NPY is in line with the earlier work that has shown that NPY stimulates food intake, promotes white fat lipid storage and decreases brown adipose tissue (BAT) thermogenesis. 25 It is unclear how NPY decreases energy expenditure, and it is likely that multiple mechanisms are involved. NPY has been shown to suppress sympathetic nervous system activity to BAT. 26 Furthermore, NPY is an important regulator of the hypothalamic-pituitary-thyroid (HPT) axis, which is critical for the regulation of energy expenditure. Earlier work has shown the projection of NPY neurons from the Arc to the PVH and the presence of the Y 1 R on thyrotropin-releasing hormone (TRH) neurons in the PVH. 1 ICV administration of NPY has also been shown to suppress PVH proTRH mRNA and circulating thyroid hormone levels. 27 Acute changes in TRH have been shown to influence oxygen consumption within a similar timeframe to the changes in energy expenditure observed in this study, 28 and ICV administration of TRH stimulates oxygen consumption, perhaps because of increased sympathetic outflow to BAT. 29 In contrast, the increase in VO 2 following ICV administration of orexin-A was associated with a marked increase in activity, consistent with its role in arousal.
Orexin-A neurons project to a number of extra-hypothala- Neuropeptides and energy balance NM Semjonous et al mic regions, including the locus coeruleus, an area important in the control of arousal and anxiety-like behaviours, and c-fos activiation is seen in this nucleus following ICV administration of orexin-A. 30 In addition to the effects on arousal, orexin-A also directly increases energy expenditure by increasing the firing rate of sympathetic nerves to BAT. 31 Unique profiles of food intake, activity and energy expenditure were also observed following injection of a-MSH, CRF and NMU. For example, NMU showed an inhibition of food intake at 5 min post injection, with the effect lasting for just over an hour. This is a rather short-lived effect compared with earlier published data, which show a sustained reduction in food intake for 12 h. 5 The ICV injections in the earlier study, however, were administered at the start of the dark phase, compared with the early light phase injections performed in the current studies, which may explain the different durations of the anorectic effects observed. In contrast, CRF produced a more rapid and potent inhibition of food intake lasting for at least 24 h. Interestingly, the rapid and potent reduction in food intake seen following ICV administration of 3 nmol CRF was accompanied by a prolonged increase in the activity lasting for up to 9 h. The ability of CRF to alter grooming and exploratory behaviour has been well established. 32, 33 In addition, de Groote et al. 34 have shown ICV injection of low-dose CRF (0.2 nmol) stimulated behavioural changes lasting for 4 h. The contrasting temporal effects of CRF on food intake and activity suggest that these responses may be regulated by different hypothalamic circuits. As opposed to the feeding effects of CRF, which are mediated by the PVH, there is 
NM Semjonous et al evidence to suggest that the locomotor effects of CRF may be mediated through activation of brainstem serotonergic systems. 35 ICV administration of CRF also increased VO 2 in line with earlier data showing that CRF stimulates sympathetic outflow to BAT. 36 The inhibitory effects of NMU on food intake have been suggested to be secondary to its effects on behaviour and the stress response. In addition to its anorexigenic effects, 5 ICV administration of NMU has also been shown to increase locomotor activity, face washing and grooming behaviour in rodents. 37 These effects are thought to be mediated through the CRF system 38 as they are absent in the CRF knockout mouse, 39 and NMU has been shown to stimulate CRF secretion from hypothalamic explants. 40 It is, therefore, difficult to ascertain NMU-specific effects, given the wide range of metabolic effects induced by CRF itself. In the present study, NMU and CRF were shown to produce effects on activity of differing durations. NMU reduced food intake for up to 1 h 10 min, whereas the effects of CRF were much more prolonged, lasting for at least 24 h. It is possible; however, that peptide half-life may also contribute towards these differences. The mechanisms through which NMU and CRF regulate food intake, activity and energy expenditure require further study.
ICV administration of the a-MSH caused a marked decrease in food intake in line with earlier published data. 41 This was associated with a rapid and potent increase in VO 2 . Although decreased food intake would be expected to reduce Neuropeptides and energy balance NM Semjonous et al energy expenditure per se, the observed increase in VO 2 is consistent with the known effects of the melanocortin system on the hypothalamic-pituitary-thyroid axis. As with NPY/AgRP neurons, pro-opiomelanocortin neurons from the Arc project onto TRH neurons in the PVH 42 and ICV administration of a-MSH to food-deprived rats potently stimulates plasma TSH. 43 Activation of the melanocortin 4 receptor (MC4R) by a-MSH is also thought to stimulate TRH gene transcription. 44 The increase in VO 2 following ICV administration of a-MSH is, therefore, likely to be due, at least in part, to its stimulatory effects on TRH neurons. An additional mechanism may be through direct activation of sympathetic outflow to BAT; the a-MSH synthetic analogue melanotan II has been shown to directly stimulate sympathetic outflow to BAT and the MC4R is expressed on BAT sympathetic nervous system outflow neurons. 45 Interestingly, the 1-nmol dose of a-MSH significantly increased both oxygen consumption and ambulatory activity, but, unlike the 3-nmol dose, had no effect on food intake. These data suggest a dose-dependent hierarchy of metabolic effects for a-MSH, and that the pathways controlling energy expenditure may be more sensitive to the effects of a-MSH than those regulating food intake. a-MSH binds to the MC3R and the MC4R with similar affinities. 46 Although the role of the MC4R in the control of both food intake and energy expenditure has been extensively studied in rodents and human beings, 47, 48 the role of the MC3R, although important, 10,49 is less well established and requires further study. It is possible, however, that the effects of a-MSH on food intake and energy expenditure are mediated by the different receptors. Further work is required to determine the exact role of the MC3R and the MC4R in mediating the effects of a-MSH on energy balance.
In summary, these data show the important quantitative and temporal differences in the response of metabolic parameters following the administration of key hypothalamic peptides. These studies that were all performed in the same experimental system, facilitate comparison between these neuropeptide systems and provide useful information on the time course and latencies of specific neuropeptides. It must be considered, however, that within the hypothalamus, neuropeptides are released in a coordinated fashion to mount an appropriate physiological response to nutritional status. Further studies are required to elucidate the precise neuronal pathways that allow the hypothalamus to sense changes in nutritional status and how these are coordinated to mediate an appropriate physiological response by altering energy intake and expenditure.
